Pharmacology/Pharmaceutical Industry
RCT: Tofacitinib reduced the risk of death or respiratory failure in patients hospitalized with Covid-19 pneumonia.
17 Jun, 2021 | 09:58h | UTCTofacitinib in Patients Hospitalized with Covid-19 Pneumonia – New England Journal of Medicine
Commentary on Twitter:
Patients who were hospitalized with #COVID19 pneumonia were randomly assigned, at a median of 10 days after symptom onset, to receive tofacitinib or placebo. At 28 days, the risk of death or respiratory failure was lower in the tofacitinib group. #IDTwitter
— NEJM (@NEJM) June 16, 2021
Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:43h | UTCCommentary: Possible Association Between COVID-19 Vaccine and Myocarditis – American College of Cardiology
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
[Press release – not published yet] CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy.
17 Jun, 2021 | 09:49h | UTCCureVac Fails in Pivotal COVID-19 Vaccine Trial With 47% Efficacy – AP / Reuters
Press release: CureVac provides update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
Commentary on Twitter (thread – click for more)
Bad new for CureVac's vaccine: it didn't make it over the efficacy bar in its 2nd interim analysis – only 47%. Not bad enough to be out for the count – it's 134 events (symptomatic Covid-19) & final is at 185 – but ….1/2 https://t.co/4GsLzgP7AT HT @noviceprize @megtirrell
— Hilda Bastian, PhD (@hildabast) June 16, 2021
Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination.
17 Jun, 2021 | 09:45h | UTCMyocarditis after BNT162b2 and mRNA-1273 Vaccination – Circulation
Related: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination.
17 Jun, 2021 | 09:41h | UTCRelated: CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.
Systematic review: Safety and effectiveness of metformin in patients with reduced renal function – safe and beneficial at a eGFR of 45 mL/min/1.73m2 or higher; possibly harmful at an eGFR of less than 30 mL/min/1.73m2.
17 Jun, 2021 | 09:37h | UTC
Commentary on Twitter
Safety of metformin for T2 diabetes in people with reduced kidney function
Associated with ⬇️ mortality and no ⬆️ risk of acidosis at an eGFR of > 45
Associated with fewer benefits & possible ⬆️ in the risk of acidosis at an eGFR <30 https://t.co/uOyarn11hM@goKDIGO pic.twitter.com/Ca05gc7FHi
— Kamlesh Khunti (@kamleshkhunti) June 16, 2021
France recommends single dose of vaccine if previous Covid infection detected.
16 Jun, 2021 | 08:24h | UTCFrance recommends single dose of vaccine if previous Covid infection detected – Rfi
Related: [Preprint] More data showing a single-dose SARS-CoV-2 mRNA vaccine may be enough in individuals with previous COVID-19. AND Another study shows a single dose of mRNA vaccine may be enough for patients with previous Covid-19
[Preprint] 2 doses of Covid vaccines (Pfizer-BioNTech or Oxford-AstraZeneca) highly effective against hospitalization from Delta variant.
15 Jun, 2021 | 09:09h | UTCNews Release: Vaccines highly effective against hospitalisation from Delta variant – Public Health England
Preprint: Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant
Commentary on Twitter
NEWS — Our new analysis shows for the first time that two doses of the #COVID19 #vaccines are highly effective against hospitalisation from the #Delta (B.1.61.2) #variant.
Read more: https://t.co/6z67CW85Zw pic.twitter.com/oyRFghHpXw
— Public Health England (@PHE_uk) June 14, 2021
(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.
15 Jun, 2021 | 09:12h | UTCCommentaries: U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 – NIH News Releases AND Novavax Covid-19 vaccine highly effective in late-stage trial, long-awaited results show – STAT AND Powerful new COVID-19 vaccine shows 90% efficacy, could boost world’s supply – Science AND Novavax COVID vaccine 90% effective in phase 3 trial – CIDRAP AND What the Novavax vaccine means for the global fight against Covid-19 – Vox
Commentary on Twitter (thread – click for more)
Good news—Novavax protein-subunit vaccine phase 3 trial shown to to be 90.4% effective overall, 100% against moderate to severe disease. This is different type from mRNA and from AZ/J&J adenovirus vaccines, and different from inactivated types. #COVID19 https://t.co/ajoGhaOUu9
— Eric Feigl-Ding (@DrEricDing) June 14, 2021
M-A: Ibuprofen and other NSAIDs superior to codeine for managing outpatient postoperative pain.
15 Jun, 2021 | 08:55h | UTCOriginal Article: Managing postoperative pain in adult outpatients: a systematic review and meta-analysis comparing codeine with NSAIDs – Canadian Medical Association Journal
Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom – “no evidence of a difference between the BNT162b2 (Pfizer-BioNTech) and ChAdOx1 (AstraZeneca) vaccines”.
14 Jun, 2021 | 08:52h | UTCImpact of vaccination on new SARS-CoV-2 infections in the United Kingdom – Nature Medicine
Commentaries on Twitter
The ChAdOx1 nCoV-19 and BNT162b2 #COVID19 #vaccines reduce incidence of new #SARSCoV2 infections by up to 65% with a single dose and up to 80% after two doses in the United Kingdom @kb_pouwels @ONS @Oxford_NDPH @UniofOxford https://t.co/K1f68MMYyO
— Nature Medicine (@NatureMedicine) June 9, 2021
First-dose vaccination with the Oxford–AstraZeneca or Pfizer–BioNTech vaccine against SARS-CoV-2 reduced the incidence of new infections in the UK by 61% and 66%, respectively, according to a study in @NatureMedicine. https://t.co/2TUFE1DeII pic.twitter.com/KuMtc1cD7l
— Nature Portfolio (@NaturePortfolio) June 9, 2021
Lab study shows sera from persons fully vaccinated with the Pfizer–BioNTech vaccine can effectively neutralize B.1.617 (Delta) and other SARS-CoV-2 variants.
14 Jun, 2021 | 08:53h | UTCBNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants – Nature
Commentary on Twitter
An in-vitro study of sera from persons fully vaccinated with the Pfizer-BioNTech vaccine found that all samples neutralized SARS-CoV-2 virus variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.618 and B.1.525. https://t.co/7lXCVe7sPY
— Carlos del Rio (@CarlosdelRio7) June 12, 2021
RCT: No difference in 30-day mortality with discontinuation vs. continuation of renin-angiotensin-system inhibitors in patients with COVID-19, but secondary and explorative analysis showed discontinuation of RAS-inhibition may lead to a faster and better recovery.
14 Jun, 2021 | 08:47h | UTCEditorial: RAS inhibition and COVID-19: more questions than answers?
Related randomized trials showing no benefit from discontinuation: Randomized trial: No benefit from discontinuing ACE Inhibitors and ARBs in patients admitted with COVID-19 AND Randomized trial: Renin–angiotensin system inhibitors can be safely continued in patients admitted to hospital with COVID-19
Perspective | Does vaccinating adults stop kids from spreading COVID too?
11 Jun, 2021 | 08:32h | UTCDoes vaccinating adults stop kids from spreading COVID too? – Nature
High COVID vaccine uptake may protect the unvaccinated.
11 Jun, 2021 | 08:34h | UTCHigh COVID vaccine uptake may protect the unvaccinated – CIDRAP
Original Study: Community-level evidence for SARS-CoV-2 vaccine protection of unvaccinated individuals – Nature Medicine
Commentaries on Twitter
Just published @NatureMedicine
Evidence that "vaccination not only protects individuals who have been vaccinated but also provides cross-protection to unvaccinated individuals in the community" as seen in kids benefiting from high % of adults vaxxedhttps://t.co/IPQo6WTFZX pic.twitter.com/jtfD93onnn— Eric Topol (@EricTopol) June 10, 2021
Nature Medicine: "On average, for each 20% increase in the number of vaccinated people in a given population, the number of positive SARS-CoV-2 tests in the unvaccinated population in the same community decreased approximately two fold." https://t.co/QhMqSbZDtc
— Niklas Fagerström (@niklasf) June 10, 2021
US donation of 500 million Pfizer vaccines could help ‘turn tide’ as Africa runs out of doses, says WHO.
11 Jun, 2021 | 08:31h | UTC
CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare.
11 Jun, 2021 | 08:28h | UTCSee also: CDC plans “emergency meeting” on rare heart inflammation following COVID-19 vaccines – CBC News
Related: Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men.
RCT: In patients with atrial fibrillation or mechanical heart valves treated with warfarin undergoing surgery, postoperative bridging treatment with low molecular weight heparin did not prevent major thromboembolism.
11 Jun, 2021 | 08:19h | UTC
Commentary on Twitter
P-E-R-S-E-V-E-R-A-N-C-E = 15 yrs from start to BMJ publication. Bottom line: in pts with atrial fibrillation or mechanical heart valves who had warfarin interrupted for a procedure, we found no benefit of
postop LMWH bridging to prevent major
thromboembolism @canvector @CIHR_ICRH https://t.co/9z0XTQgsbA— Susan R Kahn (@SusanRKahn1) June 10, 2021
WHO Report: Global antimicrobial resistance and use surveillance system.
11 Jun, 2021 | 08:22h | UTCNews Release: Record response to WHO’s call for antimicrobial resistance surveillance reports in 2020 – World Health Organization
Commentary: WHO reveals new global antibiotic resistance data, more concerns – CIDRAP
Commentary on Twitter (thread – click for more)
WHO received over 3⃣ million reports for the Global #AntimicrobialResistance and Use Surveillance System (GLASS)
The more information we have the better placed the ?
is to tackle this increasingly serious health threat.? https://t.co/ccZCzdyZUc
pic.twitter.com/DMuLwVu4rC— World Health Organization (WHO) (@WHO) June 9, 2021
Case series: Adjunct immune globulin for vaccine-induced thrombotic thrombocytopenia.
10 Jun, 2021 | 09:46h | UTC
Cohort study: the use of potentially inappropriate medications in adults with chronic kidney disease is common and linked to increased risk of hospitalization, mortality, and falls.
11 Jun, 2021 | 08:11h | UTCRisk of Potentially Inappropriate Medications in Adults With CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study – American Journal of Kidney Diseases (link to abstract – $ for full-text)
Commentary on Twitter
Risk of Potentially Inappropriate Medications in Adults With CKD: Findings From @CRICStudyhttps://t.co/1NgaqcJF5g@Rasheeda_HallMD @cjdiamantidis @sankarnava @finkjc @UMmedschool @DukeKidney #CKD #VisualAbstract pic.twitter.com/PLouT1SL9d
— AJKD (@AJKDonline) June 2, 2021
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
10 Jun, 2021 | 09:37h | UTCCommentary: The 2021 Treatment Guidelines for Rheumatoid Arthritis – Rheumatology Network
[Preprint] RECOVERY trial finds aspirin does not improve survival for patients hospitalized with COVID-19.
9 Jun, 2021 | 08:28h | UTCNews Release: RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19 – University of Oxford
Original Study: Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv
Commentary on Twitter (thread – click for more)
RECOVERY Pre-print: Aspirin
14,892 patients randomised to aspirin vs. usual care
– no impact on all-cause mortality (17% vs. 17%)
– similar results in all pre-specified subgroupshttps://t.co/ay5Xg4GBVD pic.twitter.com/aNJ09RTTOa— Martin Landray (@MartinLandray) June 8, 2021
China to offer COVID-19 vaccine to children as young as three.
9 Jun, 2021 | 08:26h | UTCChina to offer COVID-19 vaccine to children as young as three – MedicalXpress
See also: Sinovac says its vaccine is safe for children as young as 3 – Associated Press
Summary | WHO recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
9 Jun, 2021 | 08:12h | UTCOriginal Guideline: WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment – Drug-Resistant Tuberculosis Treatment
Commentary on Twitter
???@ERSpublications
WHO guidelines on the treatment of drug-resistant TB contain the latest recommendations on shorter or longer all oral treatment regimens for patients with drug-resistant TB, including the medicines to be used& supportive measures https://t.co/qeeftVYdYN pic.twitter.com/4NKNNjz3Gh— Antibiotic Steward ???Bassam Ghanem (@ABsteward) June 8, 2021